98%
921
2 minutes
20
The lack of robust subtyping for insomnia disorder (ID) led to its current classification as a uniform condition. A novel approach to subtyping ID developed a new tool, the insomnia type questionnaire (ITQ). Our research aimed to assess whether the ID subtypes identified in the general population could also be found in ID patients referred to sleep clinics in a multi-centre study throughout Spain, and to gather insights for the management of complex ID patients. The ITQ classified ID patients into the five previously described subtypes: Type 1 = 35.1%, Type 2 = 12%, Type 3 = 46.7%, Type 4 = 5.8% and Type 5 = 0.4%. Compared to the general population, there was an overrepresentation of Types 1 and 3, consistently across all participating clinical centres. The total self-reported sleep duration was 4.7 (SD 1.2) h, with no significant differences between subtypes. Type 1 patients had significantly higher scores in the Insomnia Severity Index, Inventory of Depressive Symptomatology self-rated and State-Trait Anxiety Inventory. Type 3 patients were more worried about their sleep. Type 4 had the lowest depression and anxiety scores. ITQ subtyping showed that ID patients attending sleep clinics had high scores in depression, specially Type 1 patients, who probably need a differentiated therapeutic approach. The over-representation of Type 3 patients suggests that they are more worried about their sleep than the other subtypes. These findings highlight the difficulties faced by sleep clinicians to treat complex and refractory-toto-treatment ID patients and those with comorbid insomnia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jsr.70116 | DOI Listing |
Pathol Res Pract
September 2025
Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:
Our research aims to ascertain the value of precursor and outgrowth lepidic in aiding the confirmation of multiple lung adenocarcinomas as separate primary lung cancers (SPLC). A total of 151 patients with metachronous multiple invasive adenocarcinomas were included in this study. Driver mutation tests(at least five genes: EGFR, ALK, KRAS, BRAF, and ROS1) were conducted on 302 tumors collected from 151 patients.
View Article and Find Full Text PDFBiomol Biomed
September 2025
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Coronary heart disease (CHD) is a leading cause of morbidity and mortality; patients with type 2 diabetes mellitus (T2DM) are at particularly high risk, highlighting the need for reliable biomarkers for early detection and risk stratification. We investigated whether combining the stress hyperglycemia ratio (SHR) and systemic inflammation response index (SIRI) improves CHD detection in T2DM. In this retrospective cohort of 943 T2DM patients undergoing coronary angiography, associations of SHR and SIRI with CHD were evaluated using multivariable logistic regression and restricted cubic splines; robustness was examined with subgroup and sensitivity analyses.
View Article and Find Full Text PDFNeuro Endocrinol Lett
September 2025
Manisa Celal Bayar University Faculty of Medicine, Division of Endocrinology and Metabolism, Manisa, Turkey.
Objectives: Empty sella is the herniation of the subarachnoid space into the sella turcica; either secondary to identifiable causes (e.g., surgery or radiotherapy); or spontaneously, which is termed primary empty sella (PES).
View Article and Find Full Text PDFNeuro Endocrinol Lett
September 2025
Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, China.
Background: Pheochromocytomas and paragangliomas (PPGLs) are rare catecholamine-secreting neuroendocrine tumors originating from the embryonic neural crest. Approximately 30% of PPGLs are hereditary and are frequently associated with genetic syndromes, including neurofibromatosis type 1 (NF1). Composite PPGLs, which include components of both PPGLs and related tumors such as ganglioneuromas, are extremely rare in NF1 patients.
View Article and Find Full Text PDFPain Med Case Rep
September 2023
USC University Hospital: Keck Hospital of USC, Los Angeles, CA.
Background: Peripheral nerve stimulators (PNS) are currently used for refractory cases of neuralgia, and are associated with single manufacturer use. This is the first case report describing the novel scenario where a patient received 2 neuromodulation devices from 2 different manufacturers.
Case Report: We present a 32-year-old woman with spinal muscle atrophy type 2 who received a permanent PNS implant for chronic neuralgia.